Biological product filing citing Eye paper — Ocugen, 2026-01-15
OcugenOcugenNASDAQ OCGN
Filings SEC · Quote Yahoo cited a paper published in Eye in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure is written in the press release as follows:
When a U.S.-listed company has something to inform shareholders, it files a current report with the Securities and Exchange Commission, referred to as 8-K. The item numbers in the document filed by Ocugen on 2026-01-15 were 8.01 Other Events · 9.01 Financial Statements and Exhibits. The company cited a paper published in Eye in the attached press release. If the sentence citing the paper is translated verbatim, it reads as follows:
The press release did not automatically identify the sentence citing the paper. Check the original link. Do not replace it with another paragraph.
What the reader first sees is where the company placed the paper in the press release. Next is determining whether the paper supports the company's entire claim or only part of it. To answer the latter question, one must read the full paper. This article, having read only the abstract, cannot answer it.
The scope of the paper mentioned in the abstract is limited to this.
The paper's title is A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights and it was published in Eye on 2026-01-10. The authors are affiliated with University of Nevada, Reno · Sierra Eye Associates · Duke University · University of Arizona. The summary at the beginning of the paper is called abstract. This article read only up to there. This paragraph was rewritten by a person after filtering a machine-generated draft by numerical comparison, so it is a different grade from a full-text reading and original judgment.
It is a phase 1 trial of a gene therapy injection under the retina for the first patient with Stargardt disease, a genetic retinal disease that begins at a young age and gradually causes loss of central vision. This disease progresses as toxic substances accumulate due to mutations in both copies of the causative gene, leading to atrophy of the retinal pigment epithelium, and there is currently no approved treatment. The tested therapy aims to protect the retina by regulating retinal cell homeostasis rather than correcting the causative gene, regardless of the genetic profile. Since it is a phase 1 trial assessing safety and tolerability, whether vision improves is not a question this trial answers.
The abstract does not answer; the details remain in the main text and the appendix. This article, not going further, leaves the blank as it is. Readers compare the two citations above to determine which sentence in the abstract the company cited.
A month later, the stock price was within the middle half of the sample.
The return excluding the portion attributable to market-wide movements is called excess return. Dates are recorded as trading days, counting only the days the stock market is open. In calendar terms, 20 trading days amount to about a month. The excess return for the day of the regulatory filing and the following month is presented in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | +16.9% | The extent to which it had already moved before the filing |
| On the filing day | −14.3% | The filing day or the first trading day following |
| +1~+5 trading days cumulative | −11.1% | One week |
| +1~+20 trading days cumulative | −7.7% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of −7.7% in this case is within the bottom 49% of the 142 samples, placing it in the lower half.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | top 10% | this case |
|---|---|---|---|---|---|---|
| excess return | −31.9% | −20.1% | −6.9% | +5.5% | +19.5% | −7.7% |
Half of the sample falls between the two central marks in the table. One checks in the table whether this case falls inside or outside. The sample collects cases where U.S. listed companies wrote papers in 8-K filings over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules applicable to future cases.
After the regulatory filing, the company issued such documents
After the disclosure date, the company filed three 8-Ks. Here are only the item numbers. In 8-Ks without titles, the item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be determined by the number. To learn what exactly happened, read the original text at each link.
- 2026-01-21 8-K Items 1.01, 8.01, 9.01 — Material contract execution · Other events · Financial statements · Exhibits
- 2026-01-23 8-K Items 7.01, 8.01, 9.01 — Reg FD disclosure · Other events · Financial statements · Exhibits
- 2026-02-09 8-K Item 5.02 — Officer · Director changes
What this article did not answer
This article, which reads only abstracts, cannot answer what method the paper used, what it reviewed, or how far it went. The number of times the company's paper was cited afterward can be verified again through the citation count on OpenAlexOpenAlex
Data source · Website. The next thing to check is whether the company's next 8-K again cites the same paper.
Glossary
- 8-K
- A spontaneous report submitted to the Securities and Exchange Commission when a U.S. listed company has something to inform shareholders. The type is indicated by item numbers such as earnings, contracts, and executive changes. All events in this article come from this document.
- Excess return
- The remainder obtained by subtracting the market's overall return from the stock's return. It is used to observe the company's unique movement after removing the portion attributable to the market's collective rise or fall.
- Trading day
- A count of days when the stock market is open. Weekends and holidays are excluded, so 20 trading days correspond to roughly one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary appearing at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the methods.